Our group has long been interested in the study of nuclear hormone receptor targeted therapy for the treatment of poorly differentiated cancer with a primary focus on the retinoid receptors and peroxisome-proliferator activated receptor gamma (PPARγ) as novel therapeutic targets. The gene discussed is PPARG; the disease is cancer.